London and New York-listed global biopharma GSK is to acquire Nasdaq-listed RAPT Therapeutics, a US-based, clinical-stage biopharma dedicated to developing therapies for patients living with inflammatory and immunologic diseases. GSK…
UK: GSK agrees acquisition of RAPT Therapeutics in transaction valued at US$2.2bn
…
…






